

Onconetix Inc. shares soared 23.65% after hours following clinical progress updates, new study initiation and developments in prostate cancer diagnostics.
You can purchase shares of Onconetix (NASDAQ:ONCO) through any online brokerage.
Other companies in Onconetix’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
There is no analysis for Onconetix to provide a consensus price target.
The stock price for Onconetix (NASDAQ: ONCO) is $0.6301 last updated November 4, 2026 at 6:54 PM EST.
There are no upcoming dividends for Onconetix.
Onconetix does not have any upcoming earnings scheduled.
There is no upcoming split for Onconetix.
Onconetix is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved...